Literature DB >> 16728552

Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women.

Irene Lambrinoudaki1, George Christodoulakos, Demetrios Rizos, Emmanuel Economou, John Argeitis, Sofia Vlachou, Maria Creatsa, Evangelia Kouskouni, Dimitrios Botsis.   

Abstract

OBJECTIVE: To assess the association between endogenous sex hormones and risk factors for atherosclerosis in healthy postmenopausal women.
DESIGN: Cross-sectional study in a university menopause clinic.
METHODS: Serum sex hormones and lipid-lipoprotein profile, arterial pressure, homocysteine and insulin resistance, measured by the homeostasis model assessment of insulin resistance (HOMA-IR), were assessed in 598 healthy postmenopausal women not on hormone therapy.
RESULTS: Compared with women in the lowest testosterone quartile (Q), women in the highest testosterone quartile had higher total cholesterol (Q1: 225.2 +/- 41.3 vs Q4: 246.2 +/- 38.4 mg/dl, P < 0.01), low-density lipoprotein (LDL)-cholesterol (Q1: 146.9 +/- 37.2 vs Q4: 171.8 +/- 35.3 mg/dl, P < 0.001), atherogenic index of plasma (AIP) (Q1: -0.224 +/- 0.238 vs Q4: -0.087 +/- 0.254, P < 0.01), apolipoprotein B (ApoB) (Q1: 100.7 +/- 23.1 vs Q4: 113.9 +/- 23.8 mg/dl, P < 0.001) and higher high-density lipoprotein (HDL)-cholesterol (Q1: 60.7 +/- 14.5 vs Q4: 52.9 +/- 13.0 mg/dl, P < 0.01). Accordingly, women in the highest free androgen index (FAI) quartile had higher AIP (Q1: -0.232 +/- 0.254 vs Q4: -0.078 +/- 0.243, P < 0.001) and ApoB (Q1: 102.4 +/- 25.5 vs Q4: 114.2 +/- 25.8 mg/dl, P < 0.01) and lower HDL-cholesterol (Q1: 62.0 +/- 15.7 vs Q4: 51.9 +/- 11.6 mg/dl, P < 0.001) and apolipoprotein A (Q1: 159.6 +/- 25.6 vs Q4: 147.9 +/- 24.1 mg/dl, P < 0.01) compared with women in the lowest FAI quartile. These differences remained significant after adjustment for age, body mass index (BMI), insulin resistance and social habits. The free estrogen index (FEI) exhibited similar associations to the FAI. HOMA-IR showed an independent positive association with total testosterone (Q1: 2.00 +/- 1.36 vs Q4: 2.66 +/- 1.60, P < 0.01), FAI (Q1: 1.70 +/- 1.12 vs Q4: 3.04 +/- 1.66, P < 0.001) and FEI (Q1: 1.70 +/- 0.91 vs Q4: 3.08 +/- 1.77, P < 0.001).
CONCLUSIONS: Increased androgenicity in healthy postmenopausal women is associated with an unfavorable cardiovascular risk profile. High endogenous estradiol is related to a pro-atherogenic lipid profile, an association which may, in part, be mediated by insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728552     DOI: 10.1530/eje.1.02167

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  21 in total

1.  Endogenous hormones and coronary heart disease in postmenopausal women.

Authors:  Yu Chen; Anne Zeleniuch-Jacquotte; Alan A Arslan; Oktawia Wojcik; Paolo Toniolo; Roy E Shore; Mortimer Levitz; Karen L Koenig
Journal:  Atherosclerosis       Date:  2011-03-01       Impact factor: 5.162

2.  Supplementary health benefits of linoleic Acid by improvement of vaginal cornification of ovariectomized rats.

Authors:  Saadat Parhizkar; Latiffah A Latiff
Journal:  Adv Pharm Bull       Date:  2013-02-07

3.  Research into Specific Modulators of Vascular Sex Hormone Receptors in the Management of Postmenopausal Cardiovascular Disease.

Authors:  Graciliano R A do Nascimento; Yaskara V R Barros; Amanda K Wells; Raouf A Khalil
Journal:  Curr Hypertens Rev       Date:  2009-11

4.  Trajectories of estradiol and follicle-stimulating hormone over the menopause transition and early markers of atherosclerosis after menopause.

Authors:  Samar R El Khoudary; Nanette Santoro; Hsiang-Yu Chen; Ping G Tepper; Maria M Brooks; Rebecca C Thurston; Imke Janssen; Sioban D Harlow; Emma Barinas-Mitchell; Faith Selzer; Carol A Derby; Elizabeth A Jackson; Daniel McConnell; Karen A Matthews
Journal:  Eur J Prev Cardiol       Date:  2015-09-18       Impact factor: 7.804

5.  Association of Serum Sex Hormones with Hemostatic Factors in Women On and Off Hormone Therapy: The Multiethnic Study of Atherosclerosis.

Authors:  Marlene S Williams; Mary Cushman; Pamela Ouyang; Susan R Heckbert; Rita Rastogi Kalyani; Dhanajay Vaidya
Journal:  J Womens Health (Larchmt)       Date:  2015-12-24       Impact factor: 2.681

6.  Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease.

Authors:  Glenn D Braunstein; B Delia Johnson; Frank Z Stanczyk; Vera Bittner; Sarah L Berga; Leslee Shaw; T Keta Hodgson; Maura Paul-Labrador; Ricardo Azziz; C Noel Bairey Merz
Journal:  J Clin Endocrinol Metab       Date:  2008-08-26       Impact factor: 5.958

7.  Associations of estrogen and testosterone with insulin resistance in pre- and postmenopausal women with and without hormone therapy.

Authors:  Sumika Matsui; Toshiyuki Yasui; Anna Tani; Kotaro Kunimi; Hirokazu Uemura; Satoshi Yamamoto; Akira Kuwahara; Toshiya Matsuzaki; Minoru Irahara
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

8.  Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease.

Authors:  Antonio de Padua Mansur; Tereza Cristina B F Silva; Julio Yoshio Takada; Solange Desirée Avakian; Célia Maria C Strunz; Luiz Antonio Machado César; José Mendes Aldrighi; José Antonio F Ramires
Journal:  ScientificWorldJournal       Date:  2012-06-04

Review 9.  The effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression.

Authors:  Panagiota Manolakou; Roxani Angelopoulou; Chris Bakoyiannis; Elias Bastounis
Journal:  Reprod Biol Endocrinol       Date:  2009-05-12       Impact factor: 5.211

10.  High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort study.

Authors:  Valérie Scarabin-Carré; Marianne Canonico; Sylvie Brailly-Tabard; Séverine Trabado; Pierre Ducimetière; Maurice Giroud; Joanne Ryan; Catherine Helmer; Geneviève Plu-Bureau; Anne Guiochon-Mantel; Pierre-Yves Scarabin
Journal:  J Am Heart Assoc       Date:  2012-06-22       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.